Table 6.
Associations of the combined genotypes of MGMT polymorphisms with regional lymph nodes and tumor stage of oropharyngeal cancera
| Combined genotypes (No. of risk genotypes)b | No regional lymph node metastasis (N0) |
Involvement of regional lymph nodes (N1-3) |
||
|---|---|---|---|---|
| Case/control (%) | Adjusted OR (95% CI)c | Case/control (%) | Adjusted OR (95% CI)c | |
| 0-2 | 21/567 (43.7/46.0) | 1.00 | 100/567 (36.0/46.0) | 1.00 |
| 3-4 | 27/667 (56.3/54.0) | 1.10 (0.61-1.97) | 178/667 (64.0/54.0) | 1.52 (1.16-1.89) |
| Combined genotypes (No. of risk genotypes)b | T1-2 |
T3-4 |
||
|---|---|---|---|---|
| Case/control (%) | Adjusted OR (95% CI)c | Case/control (%) | Adjusted OR (95% CI)c | |
| 0-2 | 65/567 (33.0/46.0) | 1.00 | 56/567 (43.4/46.0) | 1.00 |
| 3-4 | 132/667 (67.0/54.0) | 1.77 (1.28-2.44) | 73/667 (56.6/54.0) | 1.09 ( 0.76-1.58) |
a
N, regional lymph node involvement. N0, no regional lymph nodes; N1, N2, and N3, increasing involvement of regional lymph nodes [40].
b
The number represents the numbers of risk genotypes; the risk genotypes used for the calculation were 16195CC, 16286CC, 45996GT+TT, and 46346CA+AA genotypes).
c
ORs were obtained from a multivariate logistic regression model with adjustment for age, sex, smoking status, and alcohol use.